- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
-
Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS
- KMID: 2413200
- J Gynecol Oncol.
- 2017 Nov;28(6):e73.
- doi: 10.3802/jgo.2017.28.e73
OBJECTIVE: The chemotherapy response score (CRS) system based on histopathological examination has been recently proposed for tubo-ovarian high-grade serous carcinoma (HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study... -
- CITED
-
- Close
- SHARE
-
- Close
